Edition:
United States

Regulus Therapeutics Inc (RGLS.OQ)

RGLS.OQ on NASDAQ Stock Exchange Global Market

0.95USD
15 Dec 2017
Change (% chg)

$0.05 (+5.61%)
Prev Close
$0.90
Open
$0.90
Day's High
$0.95
Day's Low
$0.90
Volume
79,290
Avg. Vol
118,071
52-wk High
$2.75
52-wk Low
$0.79

Chart for

About

Regulus Therapeutics Inc. is a biopharmaceutical company focused on discovering and developing drugs that target microRNAs to treat a range of diseases. The Company uses its microRNA product platform to develop chemically modified, single-stranded oligonucleotides that the Company calls anti-miRs to modulate microRNAs and return... (more)

Overall

Beta: 1.56
Market Cap(Mil.): $98.76
Shares Outstanding(Mil.): 103.96
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 198.20 16.04
EPS (TTM): -- -- --
ROI: -- -11.76 34.69
ROE: -- -36.72 15.46

BRIEF-Regulus Therapeutics Q3 loss per share $0.18

* Regulus reports third quarter 2017 financial results and recent events

Nov 07 2017

BRIEF-Regulus Q3 loss per share $0.18

* Regulus reports third quarter 2017 financial results and recent events

Nov 07 2017

BRIEF-Growth Equity Opportunities reports 11.3 pct stake in Regulus Therapeutics

* Growth Equity Opportunities V reports 11.3 percent stake in Regulus Therapeutics Inc as of July 24 - SEC filing Source text: (http://bit.ly/2u4yxoS) Further company coverage:

Aug 02 2017

BRIEF-Regulus Therapeutics Q2 loss per share $0.41

* Regulus reports second quarter 2017 financial results and recent events

Aug 01 2017

BRIEF-Broadfin Capital reports 5.65 pct passive stake in Regulus Therapeutics - ‍​SEC filing

* Broadfin Capital LLC reports 5.65 percent passive stake in Regulus Therapeutics Inc as of July 20, 2017 - ‍​SEC filing Source text: (http://bit.ly/2vSFqWv) Further company coverage: (Bengaluru Newsroom: +91 806 749 1136)

Jul 24 2017

Competitors

Earnings vs. Estimates